- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01172899
Bariatric Surgery in Children. (BASIC)
The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery
Rationale:
In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.
The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)
Objective:
To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.
Study design:
Prospective randomised interventional study.
Study population:
Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.
Intervention:
Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions
Main study parameters/endpoints:
Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Limburg
-
Maastricht, Limburg, Niederlande, 6202ZA
- Maastricht University Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Aged 14 to 16
Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.
* Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.
- > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
- Demonstrate decisional capacity
Exclusion Criteria:
- Psychologically not suitable
- Pre-menarche or bone age <15 years in boys
- Obesity associated to other disorders such as hypothyroidism
- Syndromal disorders such as Prader-Willi syndrome
- Severe cardiorespiratory impairment (ASA class 3 or higher)
- Insufficiently fluid in the Dutch language
- Unwillingness to adhere to follow-up programmes
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Kontrollgruppe
|
Control group will receive standard therapy consisting of combined lifestyle interventions.
|
|
Experimental: Laparoscopic adjustable gastric band
|
Laparoscopic gastric band placement.
Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Weight
Zeitfenster: 6 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
6 months
|
|
Weight
Zeitfenster: 12 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
12 months
|
|
Weight
Zeitfenster: 24 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
24 months
|
|
Weight
Zeitfenster: 36 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
36 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Body composition
Zeitfenster: 12 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
12 months
|
|
Pubertal development
Zeitfenster: 6 months
|
Follow-up of hormonal status and Tanner stages.
|
6 months
|
|
Metabolic and endocrine changes
Zeitfenster: 6 months
|
6 months
|
|
|
Inflammatory status
Zeitfenster: 6 months
|
Measurement of serum inflammatory markers.
|
6 months
|
|
Cardiovascular abnormalities
Zeitfenster: 6 months
|
6 months
|
|
|
Non-alcoholic fatty liver disease
Zeitfenster: 6 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
6 months
|
|
Quality of life changes
Zeitfenster: 6 months
|
6 months
|
|
|
Behaviour changes
Zeitfenster: 6 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
6 months
|
|
Operative complications
Zeitfenster: up to 36 months
|
Early and late complications are being monitored
|
up to 36 months
|
|
Effects on sleep architecture
Zeitfenster: 6 months
|
6 months
|
|
|
Brain development
Zeitfenster: 6 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
6 months
|
|
Body composition
Zeitfenster: 24 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
24 months
|
|
Body composition
Zeitfenster: 36 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
36 months
|
|
Pubertal development
Zeitfenster: 12 months
|
Follow-up of hormonal status and Tanner stages.
|
12 months
|
|
Pubertal development
Zeitfenster: 24 months
|
Follow-up of hormonal status and Tanner stages.
|
24 months
|
|
Pubertal development
Zeitfenster: 36 months
|
Follow-up of hormonal status and Tanner stages.
|
36 months
|
|
Metabolic and endocrine changes
Zeitfenster: 12 months
|
12 months
|
|
|
Metabolic and endocrine changes
Zeitfenster: 24 months
|
24 months
|
|
|
Metabolic and endocrine changes
Zeitfenster: 36 months
|
36 months
|
|
|
Inflammatory status
Zeitfenster: 12 months
|
Measurement of serum inflammatory markers.
|
12 months
|
|
Inflammatory status
Zeitfenster: 24 months
|
Measurement of serum inflammatory markers.
|
24 months
|
|
Inflammatory status
Zeitfenster: 36 months
|
Measurement of serum inflammatory markers.
|
36 months
|
|
Cardiovascular abnormalities
Zeitfenster: 12 months
|
12 months
|
|
|
Cardiovascular abnormalities
Zeitfenster: 24 months
|
24 months
|
|
|
Cardiovascular abnormalities
Zeitfenster: 36 months
|
36 months
|
|
|
Non-alcoholic fatty liver disease
Zeitfenster: 12 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
12 months
|
|
Non-alcoholic fatty liver disease
Zeitfenster: 24 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
24 months
|
|
Non-alcoholic fatty liver disease
Zeitfenster: 36 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
36 months
|
|
Quality of life changes
Zeitfenster: 12 months
|
12 months
|
|
|
Quality of life changes
Zeitfenster: 24 months
|
24 months
|
|
|
Quality of life changes
Zeitfenster: 36 months
|
36 months
|
|
|
Effects on sleep architecture
Zeitfenster: 12 months
|
12 months
|
|
|
Effects on sleep architecture
Zeitfenster: 24 months
|
24 months
|
|
|
Effects on sleep architecture
Zeitfenster: 36 months
|
36 months
|
|
|
Behaviour changes
Zeitfenster: 12 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
12 months
|
|
Behaviour changes
Zeitfenster: 24 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
24 months
|
|
Behaviour changes
Zeitfenster: 36 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
36 months
|
|
Brain development
Zeitfenster: 12 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
12 months
|
|
Brain development
Zeitfenster: 24 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
24 months
|
|
Brain development
Zeitfenster: 36 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
36 months
|
|
Physical activity
Zeitfenster: 6 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
6 months
|
|
Physical activity
Zeitfenster: 12 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
12 months
|
|
Physical activity
Zeitfenster: 24
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
24
|
|
Physical activity
Zeitfenster: 36 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
36 months
|
|
Behavior towards food
Zeitfenster: 6 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
6 months
|
|
Behavior towards food
Zeitfenster: 12 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
12 months
|
|
Behavior towards food
Zeitfenster: 24 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
24 months
|
|
Behavior towards food
Zeitfenster: 36 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
36 months
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: LWE van Heurn, Professor, Maastricht University Medical Center
- Hauptermittler: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
- Hauptermittler: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- NL26279.068.09
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Fettleibigkeit, krankhaft
-
Assistance Publique - Hôpitaux de ParisRekrutierungFettleibigkeit | MorbidFrankreich
-
Erbe Elektromedizin GmbHBioscience Consulting, Inc.; Erbe do Brasil Chirúrgicos e Endoscópicos LTDAAbgeschlossenFettleibigkeit | Adipositas | MorbidBrasilien